Phase 3 Obesity Trial, Recruiting (NCT06672939)

Phase 3 Obesity Trial, Recruiting NCT06672939 Sponsor: Eli Lilly and Company Condition: Obesity

Printed from Voxsanity (voxsanity.com.au) — NCT06672939 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Obesity

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have tried at least one structured weight loss program (including diet and exercise counseling for at least 3 months) in the past, but did not lose enough weight.
Your BMI is at or above the 95th percentile for your age and sex (meaning you are in the category considered obese for your age group); OR
Your BMI is between the 85th and 95th percentile for your age and sex (considered overweight for your age group), AND you also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, prediabetes, abnormal cholesterol levels, sleep apnea, or a certain type of liver disease.

Who may not be able to join:

You have not yet started puberty (confirm with trial site)
You have lost more than 5 kg (11 pounds) in the 90 days before joining the study
You have already had, or are planning to have, weight loss surgery (such as gastric bypass, sleeve gastrectomy, or gastric banding)
Your obesity is caused by another medical condition, such as a hormonal, genetic, or brain-related disorder
You have type 1 diabetes or have ever had a serious diabetes-related crisis (such as diabetic ketoacidosis)
Your long-term blood sugar level (HbA1c) is above 9.0% at screening
You or a close family member has a history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a related condition called Multiple Endocrine Neoplasia Syndrome Type 2

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06672939

Sponsor: Eli Lilly and Company

Phase: Phase 3

Status: Recruiting

Condition: Obesity

More information: https://clinicaltrials.gov/study/NCT06672939

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have tried at least one structured weight loss program (including diet and exercise counseling for at least 3 months) in the past, but did not lose enough weight.
Your BMI is at or above the 95th percentile for your age and sex (meaning you are in the category considered obese for your age group); OR
Your BMI is between the 85th and 95th percentile for your age and sex (considered overweight for your age group), AND you also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, prediabetes, abnormal cholesterol levels, sleep apnea, or a certain type of liver disease.

Who may not be able to join:

You have not yet started puberty (confirm with trial site)
You have lost more than 5 kg (11 pounds) in the 90 days before joining the study
You have already had, or are planning to have, weight loss surgery (such as gastric bypass, sleeve gastrectomy, or gastric banding)
Your obesity is caused by another medical condition, such as a hormonal, genetic, or brain-related disorder
You have type 1 diabetes or have ever had a serious diabetes-related crisis (such as diabetic ketoacidosis)
Your long-term blood sugar level (HbA1c) is above 9.0% at screening
You or a close family member has a history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a related condition called Multiple Endocrine Neoplasia Syndrome Type 2

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Eli Lilly and Company

Registry

ClinicalTrials.gov

Start date

18 November 2024

Est. completion

1 December 2027

Where this trial is recruiting

🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇵🇱 Poland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Percent Change from Baseline in Body Mass Index (BMI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov